European Union countries have until midnight on July 31 to enter the bidding contest to provide a new home for European Medicines Agency (EMA). About 20 applications are expected, according to a report on the BBC News website.
The European Banking Authority and the EMA, both based in Canary Wharf in London, employ just over 1,000 staff between them, and the agencies will be relocated from the UK after Brexit.
“There will be fierce competition to attract the agencies’ highly skilled employees, their families and the business that comes with them. This includes 40,000 hotel stays for visitors each year,” the BBC article noted. “Countries have printed glossy brochures, posted promotional videos online and hired lobbying firms.”
The European Commission will assess the entries based on the quality of office space, job opportunities for spouses, and transport links, and European ministers will use a complicated voting system to choose the winners in November, the report added.
Philip Ward is the European Editor for Applied Clinical Trials.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.